The Claim
In patients with early-stage Alzheimer’s disease receiving weekly oral rapamycin, the estimated terminal half-life is approximately 68.9 hours (±13.6), which aligns with prior pharmacokinetic findings in other populations, suggesting similar drug elimination kinetics despite the intermittent dosing schedule.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When people with early Alzheimer's take rapamycin once a week, the drug stays in their body about as long as it does in other groups — around 69 hours — which means it leaves the body at a similar rate even with weekly dosing.
See the scientific wording
The estimated terminal half-life of weekly oral rapamycin in patients with early-stage Alzheimer’s disease is approximately 68.9 hours (±13.6), consistent with prior pharmacokinetic studies in other populations, indicating similar elimination kinetics despite the intermittent dosing regimen.
What the research says
1 studyStudy: Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease
The study gave Alzheimer’s patients rapamycin once a week and measured how long it stayed in their body. It found the drug takes about 69 hours to drop by half, which matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.